Evidence map›Paper›PMID 27118592›Full record

ArticlemBio2016

Structures of Pathogenic Fungal FKBP12s Reveal Possible Self-Catalysis Function.

Nam K Tonthat, Praveen Rao Juvvadi, Hengshan Zhang, Soo Chan Lee, Ron Venters, Leonard Spicer, William J Steinbach, Joseph Heitman, Maria A Schumacher

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Protein-Protein Interactions inFrontiers in microbiology · 2019
    Review
  18. Antimicrobial agents and chemotherapy · 2018
    Article
  19. Article
  20. FKBP Ligands-Where We Are and Where to Go?Frontiers in pharmacology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nam K TonthatDepartment of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.
Praveen Rao JuvvadiDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.
Hengshan ZhangDepartment of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.
Soo Chan LeeDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
Ron VentersDepartment of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.
Leonard SpicerDepartment of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA Department of Radiology, Duke University School of Medicine, Durham, North Carolina, USA.
William J SteinbachDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
Joseph HeitmanDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
Maria A SchumacherDepartment of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA maria.schumacher@duke.edu.
Duke University · US

Funding

Trehalose Pathway for Antifungal Targets and InhibitorsP01AI104533 · NIAID · DUKE UNIVERSITY · PI PERFECT, JOHN R. · 2015 to 2019
$9.0M
Structural Biological Development of Fungal-Specific Calcineurin InhibitorsR01AI112595 · NIAID · DUKE UNIVERSITY · PI HEITMAN, JOSEPH, SCHUMACHER, MARIA · 2014 to 2017
$2.5M
Structural Biological Development of Fungal-Specific Calcineurin InhibitorsR56AI112595 · NIAID · DUKE UNIVERSITY · PI HEITMAN, JOSEPH, HONG, JIYONG · 2020 to 2020
$669k
A Structural Approach for Treating Drug Resistant Fungal PathogensR43AI098300 · NIAID · AMPLYX PHARMACEUTICALS, INC. · PI MUTZ, MITCHELL W · 2012 to 2013
$558k
NIAID NIH HHS P01 AI104533NIAID NIH HHS R01 AI112595NIAID NIH HHS R43 AI098300NIAID NIH HHS R56 AI112595
6 · The paper itself

Abstract

unlabelledInvasive fungal infections remain difficult to treat and require novel targeting strategies. The 12-kDa FK506-binding protein (FKBP12) is a ubiquitously expressed peptidyl-prolyl isomerase with considerable homology between fungal pathogens and is thus a prime candidate for future targeting efforts to generate a panfungal strategy. Despite decades of research on FKBPs, their substrates and mechanisms of action remain unclear. Here we describe structural, biochemical, and in vivo analyses of FKBP12s from the pathogenic fungi Candida albicans, Candida glabrata, and Aspergillus fumigatus Strikingly, multiple apo A. fumigatus and C. albicans FKBP12 crystal structures revealed a symmetric, intermolecular interaction involving the deep insertion of an active-site loop proline into the active-site pocket of an adjacent subunit. Such interactions have not been observed in previous FKBP structures. This finding indicates the possibility that this is a self-substrate interaction unique to the A. fumigatus and C. albicans fungal proteins that contain this central proline. Structures obtained with the proline in the cis and trans states provide more data in support of self-catalysis. Moreover, cysteine cross-linking experiments captured the interacting dimer, supporting the idea that it forms in solution. Finally, genetic studies exploring the impact of mutations altering the central proline and an adjacent residue provide evidence that any dimeric state formed in vivo, where FKBP12 concentrations are low, is transient. Taken together, these findings suggest a unique mechanism of self-substrate regulation by fungal FKBP12s, lending further novel understanding of this protein for future drug-targeting efforts. IMPORTANCE: FKBP12 is a cis-trans peptidyl-prolyl isomerase that plays key roles in cellular protein homeostasis. FKBP12s also bind the immunosuppressive drug FK506 to inhibit the phosphatase calcineurin (CaN). CaN is required for virulence of A. fumigatus, C. albicans, C. glabrata, and other deadly fungal pathogens, marking FKBP12 and CaN as potential broad-spectrum drug targets. Here we describe structures of fungal FKBP12s. Multiple apo A. fumigatus and C. albicans FKBP12 structures reveal the insertion of a proline, conspicuously conserved in these proteins, into the active sites of adjacent molecules. This suggests that these proteins might serve as their own substrates. Cysteine disulfide trapping experiments provide support for this self-interaction and hence possible intermolecular catalysis by these enzymes.

Indexed as

Amino Acid SequenceAspergillus fumigatusCandida albicansCandida glabrataCatalytic DomainFungal ProteinsGene Expression Regulation, FungalHumansModels, MolecularMolecular Sequence DataTacrolimus Binding Protein 1AFungal ProteinsTacrolimus Binding Protein 1A

Identifiers

PMID27118592
PMCPMC4850266
OpenAlexW2343746721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.